Observational studyMedicine2025
Effectiveness and safety of intravitreal aflibercept injection for neovascular glaucoma: A single-center, retrospective, observational study in China.
Observational study in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Neovascular glaucoma: pathophysiology, diagnosis, and contemporary management.Frontiers in medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study evaluates the effectiveness and safety of intravitreal aflibercept injections in Chinese patients with neovascular glaucoma (NVG). We conducted a single-center, retrospective, observational study that identified adult Chinese patients diagnosed with NVG who received intravitreal aflibercept between January 1, 2018, and June 30, 2022, by reviewing medical records. The patients were followed-up for a month. Changes in intraocular pressure (IOP) levels and improvements in neovascularization of the iris (NVI) grades at weeks 1 and 4 compared to baseline were the main outcomes for effectiveness. Safety was assessed on the basis of the occurrence of adverse ocular events. Subgroup analysis was performed for patients with high baseline IOP (>21 mm Hg) and scheduled surgery within the follow-up period. A sum of 42 eyes from 42 patients were included in the full analysis. The included eyes had improved NVI grades by at least 1 level in 84.00% of the eyes after a week and in 91.67% after a month. The mean decline of IOP in 11 eyes that were measured at week 4 was -6.29 mm Hg compared to baseline. Similar trends were observed in the subgroups. Intravitreal aflibercept injection is safe and effective in lowering IOP and inducing NVI regression in Chinese patients, as measured by improvements in NVI grades.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.